ClinicalTrials.gg
CompletedNCT06161090Updated Dec 7, 2023

Study of CM310 in Healthy Subjects

A Phase 1 interventional study of CM310 and Placebo in Healthy, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-07.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Sep 2019, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This is a single center, randomized, double-blind, placebo-controlled, dose escalation study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers.
  • aged ≥ 18 and ≤ 65 years old.
  • With all clinical laboratory examination normal.
  • Voluntary signing of the form.

Exclusion criteria

Exclusion Criteria:

  • With a history of asthma and allergic reactions.
  • With a history of conjunctivitis and keratitis, as well as previous medical conditions.
  • With positive results from alcohol breath or urine drug abuse testing.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Group 75 mg

    CM310 Recombinant Humanized Monoclonal Antibody Injection

    Biological: CM310

  • Experimental
    Group 150 mg

    CM310 Recombinant Humanized Monoclonal Antibody Injection

    Biological: CM310

  • Experimental
    Group 300 mg

    CM310 Recombinant Humanized Monoclonal Antibody Injection

    Biological: CM310

  • Experimental
    Group 600 mg

    CM310 Recombinant Humanized Monoclonal Antibody Injection

    Biological: CM310

  • Placebo comparator
    Placebo

    Placebo, Subcutaneous

    Drug: Placebo

Interventions

  • BiologicalCM310

    CM310 injection

  • DrugPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Adverse event

    Incidence of adverse events.

    Time frame: up to Week 9

07

Study locations

1 site
  • PKUCare Luzhong Hospital
    Zibo, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Jan 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 7, 2023
StartActual
Sep 3, 2019
Primary completionActual
Jan 13, 2020
CompletionActual
Jan 13, 2020
Last update
Dec 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06161090
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Sep 3, 2019
Primary completion
Jan 13, 2020
Completion
Jan 13, 2020
Last update
Dec 7, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion